Radiopharm Presents Positive RAD202 Data For HER2-Positive Solid Tumors At EMIM 2025 March 17, 2025 — 11:05 am EDT Written by RTTNews.com for RTTNews -> ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor.

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program. ... is looking at ELVN-002 in combination with Roche’s Herceptin for patients with HER2-positive colorectal cancer.

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors ...

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner ...